Yibai Pharmaceutical announced that in the first half of 2026, it achieved operating income of 689 million yuan, a year-on-year decrease of 30.58%; net loss attributable to shareholders of listed companies of 803.78 million yuan, net loss of 19.021 million yuan for the same period last year; and net loss of 87.4543 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss. Basic earnings per share -$0.102, and the weighted average return on net assets was -3.741%. Net cash flow from operating activities was 64,1415 million yuan, a year-on-year decrease of 62.39%. There are no profit distribution plans for the reporting period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.